REGN SignalReason for this trade
1: Market is taking pullback from trendline
2: market is near high supply area
629.22MXN
67.15 BMXN
222.80 BMXN
105.09 M
About REGENERON PHARMACEUTICALS INC
Sector
CEO
Leonard S. Schleifer
Headquarters
Tarrytown
Website
Employees (FY)
13.45 K
Founded
1988
ISIN
US75886F1075
FIGI
BBG00BNKGPS2
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where REGN is featured.
Frequently Asked Questions
The current price of REGN is 15326.56 MXN — it has decreased by 2.96% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange REGENERON PHARMACEUTICALS INC stocks are traded under the ticker REGN.
REGENERON PHARMACEUTICALS INC is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
REGN stock is 3.05% volatile and has beta coefficient of 0.62. Check out the list of the most volatile stocks — is REGENERON PHARMACEUTICALS INC there?
One year price forecast for REGENERON PHARMACEUTICALS INC has a max estimate of 20179.56 MXN and a min estimate of 12219.75 MXN.
REGN earnings for the last quarter are 202.02 MXN whereas the estimation was 186.19 MXN which accounts for 8.50% surprise. Estimated earnings for the next quarter are 182.26 MXN. See more details about REGENERON PHARMACEUTICALS INC earnings.
REGENERON PHARMACEUTICALS INC revenue for the last quarter amounts to 58.61 B MXN despite the estimated figure of 56.34 B MXN. In the next quarter revenue is expected to reach 55.96 B MXN.
Yes, you can track REGENERON PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
REGN stock has fallen by 2.96% compared to the previous week, the month change is a 4.31% fall, over the last year REGENERON PHARMACEUTICALS INC has showed a 5.11% increase.
REGN net income for the last quarter is 19.70 B MXN, while the quarter before that showed 17.57 B MXN of net income which accounts for 12.12% change. Track more REGENERON PHARMACEUTICALS INC financial stats to get the full picture.
Today REGENERON PHARMACEUTICALS INC has the market capitalization of 1.68 T, it has decreased by 3.06% over the last week.
No, REGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, REGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REGENERON PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 13.45 K employees. See our rating of the largest employees — is REGENERON PHARMACEUTICALS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So REGENERON PHARMACEUTICALS INC technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating REGENERON PHARMACEUTICALS INC stock shows the buy signal. See more of REGENERON PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on REGENERON PHARMACEUTICALS INC future price: according to them, REGN price has a max estimate of 20179.56 MXN and a min estimate of 12219.75 MXN. Read a more detailed REGENERON PHARMACEUTICALS INC forecast: see what analysts think of REGENERON PHARMACEUTICALS INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REGENERON PHARMACEUTICALS INC EBITDA is 79.86 B MXN, and current EBITDA margin is 36.36%. See more stats in REGENERON PHARMACEUTICALS INC financial statements.